Status:
COMPLETED
Valsartan Intensified Primary Care Reduction of Blood Pressure Study
Lead Sponsor:
Novartis Pharmaceuticals
Collaborating Sponsors:
Baker Heart and Diabetes Institute
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study will assess the efficacy of an intensive blood pressure management strategy compared to usual care in a primary care (general practice) setting.
Eligibility Criteria
Inclusion
- newly diagnosed or currently treated hypertensive patients who have not attained their blood pressure target and require active pharmacological treatment as recommended by the local guidelines as judged by the general practitioner
Exclusion
- significantly elevated blood pressure (severe hypertension)
- requiring 3 or more antihypertensive drugs
- severe kidney disease or dialyses
- clinical diagnosis requiring concomitant therapy with antihypertensive treatment that would be outside the therapies allowed under study protocol
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
2337 Patients enrolled
Trial Details
Trial ID
NCT00902304
Start Date
July 1 2009
End Date
July 1 2011
Last Update
December 4 2012
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
East Hanover, New Jersey, United States, 07936
2
Professor Garry Jennings-Co Principal Investigator
Melbourne, Australia
3
Professor Simon Stewart-Principal Investigator
Melbourne, Australia